Switch theme
Sign up to access all valuation multiples
Krka DD engages in the development, production, marketing, and sales of human health products (prescription pharmaceuticals and non-prescription products), animal health products, health resorts, and tourist services. The company products in Prescription pharmaceuticals include Cardiovascular diseases, Infections, and Oncology; Non-prescription products include Cold and cough products, nasal products, vitamins and minerals, and hair care products; and Animal health products include Antimicrobials and disinfectants, among others. It operates across the European Union, South-East Europe, East Europe region, and Others. The company derives a majority of its revenue from the European Union.
1954
11.8K+
LTM Revenue $2.1B
LTM EBITDA $566M
$5.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Krka has a last 12-month revenue of $2.1B and a last 12-month EBITDA of $566M.
In the most recent fiscal year, Krka achieved revenue of $1.9B and an EBITDA of $507M.
Krka expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Krka valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $1.8B | $1.9B | XXX | XXX | XXX |
| Gross Profit | $957M | $1.0B | XXX | XXX | XXX |
| Gross Margin | 52% | 54% | XXX | XXX | XXX |
| EBITDA | $582M | $507M | XXX | XXX | XXX |
| EBITDA Margin | 32% | 26% | XXX | XXX | XXX |
| Net Profit | $332M | $390M | XXX | XXX | XXX |
| Net Margin | 18% | 20% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Krka's stock price is EUR 169 (or $182).
Krka has current market cap of EUR 5.2B (or $5.6B), and EV of EUR 4.6B (or $5.0B).
See Krka trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.0B | $5.6B | XXX | XXX | XXX | XXX | $12.46 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Krka has market cap of $5.6B and EV of $5.0B.
Krka's trades at 2.4x LTM EV/Revenue multiple, and 8.8x LTM EBITDA.
Analysts estimate Krka's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Krka and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $5.0B | XXX | XXX | XXX |
| EV/Revenue | 2.6x | XXX | XXX | XXX |
| EV/EBITDA | 9.8x | XXX | XXX | XXX |
| P/E | 16.6x | XXX | XXX | XXX |
| P/E/Growth | 1.3x | XXX | XXX | XXX |
| EV/FCF | 52.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpKrka's NTM/LTM revenue growth is 6%
Krka's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Krka's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Krka's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Krka and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -13% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 32% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 19% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 6% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 10% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 35% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Krka acquired XXX companies to date.
Last acquisition by Krka was XXXXXXXX, XXXXX XXXXX XXXXXX . Krka acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Krka founded? | Krka was founded in 1954. |
| Where is Krka headquartered? | Krka is headquartered in Slovenia. |
| How many employees does Krka have? | As of today, Krka has 11.8K+ employees. |
| Is Krka publicy listed? | Yes, Krka is a public company listed on LJU. |
| What is the stock symbol of Krka? | Krka trades under KRKG ticker. |
| When did Krka go public? | Krka went public in 1997. |
| Who are competitors of Krka? | Similar companies to Krka include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Krka? | Krka's current market cap is $5.6B |
| What is the current revenue of Krka? | Krka's last 12-month revenue is $2.1B. |
| What is the current EBITDA of Krka? | Krka's last 12-month EBITDA is $566M. |
| What is the current EV/Revenue multiple of Krka? | Current revenue multiple of Krka is 2.4x. |
| What is the current EV/EBITDA multiple of Krka? | Current EBITDA multiple of Krka is 8.8x. |
| What is the current revenue growth of Krka? | Krka revenue growth between 2023 and 2024 was 5%. |
| Is Krka profitable? | Yes, Krka is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
